The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence

Bibliography

• The World Health Report 2004 – Global Status Report on Alcohol. Geneva: World Health Organization, 2004
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Washington DC: American Psychiatric Press; 1994
   Google Scholar
• International Statistical Classification of Diseases and Related Health Problems (ICD-10) Tenth Revision. 2nd edition. Geneva: World Health Organization; 2004
   Google Scholar
• Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 2006;111:855-76
   PubMed Web of Science ®Google Scholar
• Fuller RK, Branchey L, Brightwell DR, Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986;256:1449-55
   PubMed Web of Science ®Google Scholar
• Mark TL, Kranzler HR, Poole VH, Barriers to the use of medications to treat alcoholism. Am J Addict 2003;12:281-94
   PubMed Web of Science ®Google Scholar
• Oslin DW, Lynch KG, Pettinati HM, A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res 2008;32:1299-308
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Rhines KC, Rhines JS, Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 1997;54:737-42
   PubMed Web of Science ®Google Scholar
• Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-28
   PubMed Web of Science ®Google Scholar
• Mann KF, Kiefer F. Acamprosate in the treatment of alcoholism: mechanisms and perspectives. Future Neurol 2006;1:277-84
   Google Scholar
• Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006;40:383-93
   PubMed Web of Science ®Google Scholar
• De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005;19:517-37
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Neurobiology of addiction. London: Academic Press; 2006
   Google Scholar
• Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction 1995;90:1179-88
   PubMed Web of Science ®Google Scholar
• Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482-90
   PubMed Web of Science ®Google Scholar
• Mihic SJ, Harris RA. Alcohol actions at the GABAA receptor/chloride channel complex. In: Deitrich RA & Erwin VG, editors, Pharmacological effects of ethanol on the nervous system. Boca Raton, FL: CRC Press, Inc; 1996. p. 51-72
   Google Scholar
• Nevo I, Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 1995;26:305-36
   PubMed Web of Science ®Google Scholar
• Koob GF, Roberts AJ, Schulteis G, Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998;22:3-9
   PubMed Web of Science ®Google Scholar
• Chabenat C, Ladure P, Moore N, Application of an analytical method to calcium acetylhomotaurinate determination in urine. Arzneimittelforschung 1989;39:1413-4
   PubMed Web of Science ®Google Scholar
• Girault J, Gobin P, Fourtillan JB. Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry. J Chromatogr 1990;530:295-305
   PubMed Web of Science ®Google Scholar
• Saivin S, Hulot T, Chabac S, Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35:331-45
   PubMed Web of Science ®Google Scholar
• Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997;53:1038-53
   PubMed Web of Science ®Google Scholar
• Durbin P, Hulot T, & Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, editor, Acamprosate in relapse prevention of alcoholism. Proceedings of the 1st Campral Symposium. Stuttgart, Germany: Springer; 1995. p. 47-64
   Google Scholar
• Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl 2005;15:148-56
   PubMedGoogle Scholar
• Johnson BA, O'Malley SS, Ciraulo DA, Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 2003;23:281-93
   PubMed Web of Science ®Google Scholar
• Mehta AK, Ticku MK. Ethanol potentiation of GABAergic transmission in cultured spinal cord neurons involves gamma-aminobutyric acidA-gated chloride channels. J Pharmacol Exp Ther 1988;246:558-64
   PubMed Web of Science ®Google Scholar
• Suzdak PD, Schwartz RD, Skolnick P, Paul SM. Alcohols stimulate gamma-aminobutyric acid receptor-mediated chloride uptake in brain vesicles: correlation with intoxication potency. Brain Res 1988;444:340-5
   PubMed Web of Science ®Google Scholar
• Allan AM, Burnett D, Harris RA. Ethanol-induced changes in chloride flux are mediated by both GABA(A) and GABA(B) receptors. Alcohol Clin Exp Res 1991;15:233-7
   PubMed Web of Science ®Google Scholar
• Lima-Landman MT, Albuquerque EX. Ethanol potentiates and blocks NMDA-activated single-channel currents in rat hippocampal pyramidal cells. FEBS Lett 1989;247:61-7
   PubMed Web of Science ®Google Scholar
• Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989;243:1721-4
   PubMed Web of Science ®Google Scholar
• Nie Z, Madamba SG, Siggins GR. Ethanol inhibits glutamatergic neurotransmission in nucleus accumbens neurons by multiple mechanisms. J Pharmacol Exp Ther 1994;271:1566-73
   PubMed Web of Science ®Google Scholar
• Simson PE, Criswell HE, Johnson KB, Ethanol inhibits NMDA-evoked electrophysiological activity in vivo. J Pharmacol Exp Ther 1991;257:225-31
   PubMed Web of Science ®Google Scholar
• Carta M, Ariwodola OJ, Weiner JL, Valenzuela CF. Alcohol potently inhibits the kainate receptor-dependent excitatory drive of hippocampal interneurons. Proc Natl Acad Sci U S A 2003;100:6813-8
   PubMed Web of Science ®Google Scholar
• Gessa GL, Muntoni F, Collu M, Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985;348:201-3
   PubMed Web of Science ®Google Scholar
• Brodie MS, Shefner SA, Dunwiddie TV. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 1990;508:65-9
   PubMed Web of Science ®Google Scholar
• Leslie SW, Barr E, Chandler J, Farrar RP. Inhibition of fast- and slow-phase depolarization-dependent synaptosomal calcium uptake by ethanol. J Pharmacol Exp Ther 1983;225:571-5
   PubMed Web of Science ®Google Scholar
• Dildy-Mayfield JE, Machu T, Leslie SW. Ethanol and voltage- or receptor-mediated increases in cytosolic Ca2+ in brain cells. Alcohol 1992;9:63-9
   PubMed Web of Science ®Google Scholar
• Mhatre MC, Pena G, Sieghart W, Ticku MK. Antibodies specific for GABAA receptor alpha subunits reveal that chronic alcohol treatment down-regulates alpha-subunit expression in rat brain regions. J Neurochem 1993;61:1620-5
   PubMed Web of Science ®Google Scholar
• Morrow AL, Suzdak PD, Karanian JW, Paul SM. Chronic ethanol administration alters gamma-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl- uptake in cerebral cortical synaptoneurosomes. J Pharmacol Exp Ther 1988;246:158-64
   PubMed Web of Science ®Google Scholar
• Engberg G, Hajos M. Alcohol withdrawal reaction as a result of adaptive changes of excitatory amino acid receptors. Naunyn Schmiedebergs Arch Pharmacol 1992;346:437-41
   PubMed Web of Science ®Google Scholar
• Chandler LJ, Newsom H, Sumners C, Crews F. Chronic ethanol exposure potentiates NMDA excitotoxicity in cerebral cortical neurons. J Neurochem 1993;60:1578-81
   PubMed Web of Science ®Google Scholar
• Snell LD, Tabakoff B, Hoffman PL. Radioligand binding to the N-methyl-D-aspartate receptor/ionophore complex: alterations by ethanol in vitro and by chronic in vivo ethanol ingestion. Brain Res 1993;602:91-8
   PubMed Web of Science ®Google Scholar
• Hoffman PL, Tabakoff B. The role of the NMDA receptor in ethanol withdrawal. EXS 1994;71:61-70
   PubMedGoogle Scholar
• Davidson M, Shanley B, Wilce P. Increased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study. Brain Res 1995;674:91-6
   PubMed Web of Science ®Google Scholar
• Ripley TL, Little HJ. Ethanol withdrawal hyperexcitability in vitro is selectively decreased by a competitive NMDA receptor antagonist. Brain Res 1995;699:1-11
   PubMed Web of Science ®Google Scholar
• Stephens DN. A glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands. Behav Pharmacol 1995;6:425-46
   PubMed Web of Science ®Google Scholar
• Diana M, Pistis M, Muntoni A, Marked decrease of A10 dopamine neuronal firing during ethanol withdrawal syndrome in rats. Eur J Pharmacol 1992;221:403-4
   PubMed Web of Science ®Google Scholar
• Diana M, Pistis M, Muntoni A, Gessa G. Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence. Neuroscience 1996;71:411-5
   PubMed Web of Science ®Google Scholar
• Shen RY, Chiodo LA. Acute withdrawal after repeated ethanol treatment reduces the number of spontaneously active dopaminergic neurons in the ventral tegmental area. Brain Res 1993;622:289-93
   PubMed Web of Science ®Google Scholar
• Bailey CP, Manley SJ, Watson WP, Chronic ethanol administration alters activity in ventral tegmental area neurons after cessation of withdrawal hyperexcitability. Brain Res 1998;803:144-52
   PubMed Web of Science ®Google Scholar
• Messing RO, Carpenter CL, Diamond I, Greenberg DA. Ethanol regulates calcium channels in clonal neural cells. Proc Natl Acad Sci U S A 1986;83:6213-5
   PubMed Web of Science ®Google Scholar
• Dolin S, Little H, Hudspith M, Increased dihydropyridine-sensitive calcium channels in rat brain may underlie ethanol physical dependence. Neuropharmacology 1987;26:275-9
   PubMed Web of Science ®Google Scholar
• Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med 2007;1:115-25
   PubMed Web of Science ®Google Scholar
• Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000;60:343-62
   PubMed Web of Science ®Google Scholar
• Naassila M, Hammoumi S, Legrand E, Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998;22:802-9
   PubMed Web of Science ®Google Scholar
• al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998;22:810-4
   PubMed Web of Science ®Google Scholar
• Grant KA, Valverius P, Hudspith M, Tabakoff, B. Ethanol withdrawal seizures and the NMDA receptor complex. Eur J Pharmacol 1990;176:289-96
   PubMed Web of Science ®Google Scholar
• Dolin SJ, Little HJ. Are changes in neuronal calcium channels involved in ethanol tolerance. J Pharmacol Exp Ther 1989;250:985-91
   PubMed Web of Science ®Google Scholar
• Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 1998;49:173-84
   PubMed Web of Science ®Google Scholar
• Tsai GE, Ragan P, Chang R, Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 1998;155:726-32
   PubMed Web of Science ®Google Scholar
• Dahchour A, De Witte P. Bolo N, Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 1998;82:107-14
   PubMed Web of Science ®Google Scholar
• Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol 2000;394:221-31
   PubMed Web of Science ®Google Scholar
• Koob GF, Mason BJ, De Witte P, Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 2002;26:586-92
   PubMed Web of Science ®Google Scholar
• Staner L, Boeijinga P, Danel T, Effects of acamprosate on sleep during alcohol withdrawal: a double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects. Alcohol Clin Exp Res 2006;30:1492-9
   PubMed Web of Science ®Google Scholar
• Boismare F, Daoust M, Moore N, A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984;21:787-9
   PubMed Web of Science ®Google Scholar
• Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987;4:97-102
   PubMed Web of Science ®Google Scholar
• Spanagel R, Hölter SM, Allingham K, Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996;305:39-44
   PubMed Web of Science ®Google Scholar
• Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998;18:125-33
   PubMed Web of Science ®Google Scholar
• Bachteler D, Economidou D, Danysz W, The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology 2005;30:1104-10
   PubMed Web of Science ®Google Scholar
• Dahchour A, De Witte P. Acamprosate decreases the hypermotility during repeated ethanol withdrawal. Alcohol 1999;18:77-81
   PubMed Web of Science ®Google Scholar
• Cole JC, Littleton JM, Little HJ. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology (Berl) 2000;147:403-11
   PubMed Web of Science ®Google Scholar
• Spanagel R, Putzke J, Stefferl A, Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 1996;305:45-50
   PubMed Web of Science ®Google Scholar
• Namkoong K, Lee BO, Lee PG, Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003;38:135-41
   PubMed Web of Science ®Google Scholar
• Lhuintre JP, Daoust M, Moore ND, Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985;1:1014-6
   PubMed Web of Science ®Google Scholar
• Lhuintre JP, Moore N, Tran G, Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990;25:613-22
   PubMed Web of Science ®Google Scholar
• Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? J Pharm Belg 1996;51:65-8
   PubMedGoogle Scholar
• Pelc I, Verbanck P, Le Bon O, Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 1997;171:73-7
   PubMed Web of Science ®Google Scholar
• Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol 2004;65:136-9
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60:92-9
   PubMed Web of Science ®Google Scholar
• Morley KC, Teesson M, Reid SC, Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006;101:1451-62
   PubMed Web of Science ®Google Scholar
• Pelc I, Le Bon O, Verbanck P, Calcium-acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multi-centre study. In: Naranjo CA & Sellers EM, editors, Novel pharmacological interventions for alcoholism. New York, NY: Springer-Verlag; 1992. p. 348-52
   Google Scholar
• Ladewig D, Knecht T, Lehert P, Fendl A. Acamprosate--a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 1993;50:182-8
   PubMedGoogle Scholar
• Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997;3:129-37
   Web of Science ®Google Scholar
• Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 1997;92:1537-46
   PubMed Web of Science ®Google Scholar
• Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35:176-87
   PubMed Web of Science ®Google Scholar
• Tempesta E, Janiri L, Bignamini A, Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000;35:202-9
   PubMed Web of Science ®Google Scholar
• Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol 2001;36:413-8
   PubMed Web of Science ®Google Scholar
• Paille FM, Guelfi JD, Perkins AC, Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995;30:239-47
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-80
   PubMed Web of Science ®Google Scholar
• Whitworth AB, Fischer F, Lesch OM, Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42
   PubMed Web of Science ®Google Scholar
• Barrias JA, Chabac S, Ferreira L, Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clin 1997;18:149-60
   Google Scholar
• Besson J, Aeby F, Kasas A, Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22:573-9
   PubMed Web of Science ®Google Scholar
• Anton RF, O'Malley SS, Ciraulo DA, Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-17
   PubMed Web of Science ®Google Scholar
• Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 2003;12:144-8
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001;25:1335-41
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Selby P, Negrete JC. Meta-analyses of placebo-controlled trials of acamprosate for the treatment of alcohol dependence: impact of the Combined Pharmacotherapies and Behavior Interventions Study. J Addict Med 2009;3:74-82
   PubMed Web of Science ®Google Scholar
• Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004;28:51-63
   PubMed Web of Science ®Google Scholar
• Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008;22:11-23
   PubMed Web of Science ®Google Scholar
• Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother 2005;6:2103-15
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati HM, Lynch KG, Initiating acamprosate within-detoxification versus post-detoxification in the treatment of alcohol dependence. Addict Behav 2009;34:581-6
   PubMed Web of Science ®Google Scholar
• Schneider E, Saikali K, Zhang D, Gage A. Acamprosate decreases the severity and duration of relapse and aids in post-relapse recovery of abstinence in alcohol-dependent patients. Presented at: 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada, May 20-25, 2006
   Google Scholar
• Chick J, Lehert P, Landron F. Plinius Major Society. Does acamprosate improve reduction of drinking as well as aiding abstinence? J Psychopharmacol 2003;17:397-402
   PubMed Web of Science ®Google Scholar
• Campral [package insert]. Saint Louis, MO: Forest Pharmaceuticals, Inc.; 2005
   Google Scholar
• Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med 2008;2:40-50
   PubMed Web of Science ®Google Scholar
• Mason BJ. Acamprosate. Recent Dev Alcohol 2003;16:203-15
   PubMedGoogle Scholar
• Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001;62(Suppl 20):42-8
   PubMedGoogle Scholar
• Gross MM, Goodenough DR, Hastey J, Lewis E. Experimental study of sleep in chronic alcoholics before, during, and after four days of heavy drinking with a nondrinking comparison. Ann N Y Acad Sci 1973;215:254-65
   PubMed Web of Science ®Google Scholar
• Gross MM, Hastey JM. Slow wave sleep and carry-over of functional tolerance and physical dependence in alcoholics. Adv Exp Med Biol 1975;59:477-93
   PubMedGoogle Scholar
• Williams HL, Rundell OH Jr. Altered sleep physiology in chronic alcoholics: reversal with abstinence. Alcohol Clin Exp Res 1981;5:318-25
   PubMed Web of Science ®Google Scholar
• Adamson J, Burdick JA. Sleep of dry alcoholics. Arch Gen Psychiatry 1973;28:146-9
   PubMed Web of Science ®Google Scholar
• Brower KJ, Aldrich MS, Robinson EA, Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001;158:399-404
   PubMed Web of Science ®Google Scholar
• Landolt HP, Gillin JC. Sleep abnormalities during abstinence in alcohol-dependent patients. Aetiology and management. CNS Drugs 2001;15:413-25
   PubMed Web of Science ®Google Scholar
• Malenka RC. The role of postsynaptic calcium in the induction of long-term potentiation. Mol Neurobiol 1991;5:289-95
   PubMed Web of Science ®Google Scholar
• O'Mahony JF, Doherty B. Intellectual impairment among recently abstinent alcohol abusers. Br J Clin Psychol 1996;35:77-83
   PubMed Web of Science ®Google Scholar
• Schneider U, Wohlfarth K, Schulze-Bonhage A, Effects of acamprosate on memory in healthy young subjects. J Stud Alcohol 1999;60:172-5
   PubMed Web of Science ®Google Scholar
• Smith DE, McCrady BS. Cognitive impairment among alcoholics: impact on drink refusal skill acquisition and treatment outcome. Addict Behav 1991;16:265-74
   PubMed Web of Science ®Google Scholar
• McCrady BS, Smith DE. Implications of cognitive impairment for the treatment of alcoholism. Alcohol Clin Exp Res 1986;10:145-9
   PubMed Web of Science ®Google Scholar
• Mason BJ, Goodman AM, Dixon RM, A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606
   PubMed Web of Science ®Google Scholar
• Mark TL, Kassed CA, Vandivort-Warren R, Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 2009;99:345-9
   PubMed Web of Science ®Google Scholar
• Schadlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study. Pharmacoeconomics 1998;13:719-30
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Neeser K, Weiss C, The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol 2000;35:478-92
   PubMed Web of Science ®Google Scholar
• Annemans L, Vanoverbeke N, Tecco J, D’Hooghe D. Economic evaluation of campral (acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur Addict Res 2000;6:71-8
   PubMed Web of Science ®Google Scholar
• Rychlik R, Siedentop H, Pfeil T, Daniel D. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur Addict Res 2003;9:59-64
   PubMed Web of Science ®Google Scholar
• Koob GF, Lloyd GK, Mason BJ. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov 2009;8:500-15
   PubMed Web of Science ®Google Scholar